ir.loxooncology.com
Loxo Oncology - Investor Relations - NASDAQ:LOXOLoxo Oncology, Inc.'s Investor Relations website contains information about our business for stockholders, potential investors, and financial analysts.
http://ir.loxooncology.com/
Loxo Oncology, Inc.'s Investor Relations website contains information about our business for stockholders, potential investors, and financial analysts.
http://ir.loxooncology.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.4 seconds
16x16
PAGES IN
THIS WEBSITE
11
SSL
EXTERNAL LINKS
25
SITE IP
64.207.189.192
LOAD TIME
0.432 sec
SCORE
6.2
Loxo Oncology - Investor Relations - NASDAQ:LOXO | ir.loxooncology.com Reviews
https://ir.loxooncology.com
Loxo Oncology, Inc.'s Investor Relations website contains information about our business for stockholders, potential investors, and financial analysts.
ir.loxooncology.com
Stock Information | Loxo Oncology
http://ir.loxooncology.com/historic-stock-lookup
About Genetically Defined Cancers. Access to Investigational Therapies. Last Updated: 7 Nov, 2016 2:08 PM (EDT). Minimum 20 minute delay. Last Updated: 7 Nov, 2016 2:08 PM (EDT) Minimum 20 minute delay. Historic Stock Lookup (LOXO). LOXO launched on August 1, 2014. November 4, 2016. No data was available for the selected date. Or, Amount Invested (USD). No data was available for the selected date. November 4, 2016. Quotes delayed at least 15 minutes. Market data provided by Interactive Data. Access To In...
Stock Information | Loxo Oncology
http://ir.loxooncology.com/stock-information
About Genetically Defined Cancers. Access to Investigational Therapies. Last Updated: 7 Nov, 2016 2:08 PM (EDT). Minimum 20 minute delay. Last Updated: 7 Nov, 2016 2:08 PM (EDT) Minimum 20 minute delay. Historic Stock Lookup (LOXO). LOXO launched on August 1, 2014. November 4, 2016. No data was available for the selected date. Or, Amount Invested (USD). No data was available for the selected date. November 4, 2016. Quotes delayed at least 15 minutes. Market data provided by Interactive Data. Access To In...
Investor FAQs | Loxo Oncology
http://ir.loxooncology.com/investor-faqs
About Genetically Defined Cancers. Access to Investigational Therapies. When was Loxo Oncology founded? Loxo Oncology was founded in 2013. Where is Loxo Oncology incorporated? Loxo Oncology was incorporated in the state of Delaware in May 2013. Where is Loxo Oncology’s corporate headquarters? 281 Tresser Boulevard, 9th Floor Stamford, CT 06901 Phone: (203)-653-3880. Who are the members of Loxo Oncology’s Board of Directors? You can view our Board of Directors by visiting the Board of Directors. Loxo Onco...
Financials & Filings | Loxo Oncology
http://ir.loxooncology.com/sec-filings
About Genetically Defined Cancers. Access to Investigational Therapies. Nov 2, 2016. Nov 2, 2016. Quarterly report which provides a continuing view of a company’s financial position. Nov 2, 2016. Report of unscheduled material events or corporate event. Sep 23, 2016. A statement of beneficial ownership of common stock by certain persons. Sep 23, 2016. An amendment to the SC 13G filing. Sep 13, 2016. An amendment to a SC 13D filing. Sep 9, 2016. Statement of changes in beneficial ownership of securities.
Press Releases | Loxo Oncology
http://ir.loxooncology.com/press-releases
About Genetically Defined Cancers. Access to Investigational Therapies. Loxo Oncology Announces Second Quarter 2016 Financial Results. Released on Aug 03, 2016. Loxo Oncology to Announce Second Quarter 2016 Financial Results. Released on Jul 27, 2016. Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101. Released on Jul 13, 2016. Released on Jun 15, 2016. Loxo Oncology to Present at the JMP Securities Life Sciences Conference. Released on Jun 14, 2016.
TOTAL PAGES IN THIS WEBSITE
11
Patients & Caregivers | Loxo Oncology
https://www.loxooncology.com/patients-caregivers
About Genetically Defined Cancers. Access to Investigational Therapies. Patients are at the heart of everything we do at Loxo Oncology, and we continue to be motivated by one goal: to dramatically improve the lives of people living with cancer by developing medicines against genetically defined targets driving cancer growth. Advances in human genetics are shedding new light on the molecular roots of disease, and our science. We invite you to visit our resources. Section contains information on our progra...
Careers at Loxo | Loxo Oncology
https://www.loxooncology.com/careers
About Genetically Defined Cancers. Access to Investigational Therapies. We are highly committed to building a company that is focused on helping patients overcome cancer through creating highly selective therapies that target specific genetic alterations. We are looking for people who embrace innovation, challenge the status quo and believe in the power of precision medicine. Most importantly, we are looking for people who believe that they can make a real difference. Overview of the Role:. Provides feed...
About Us | Loxo Oncology
https://www.loxooncology.com/company
About Genetically Defined Cancers. Access to Investigational Therapies. Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. We base our approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. About Genetically Defined Cancers. Access To Investigational Therapies.
Pipeline | Loxo Oncology
https://www.loxooncology.com/pipeline
About Genetically Defined Cancers. Access to Investigational Therapies. We are developing a pipeline of purpose-built, targeted medicines against genetic drivers of cancer. By designing highly selective medicines, we have the potential to deliver treatments that increase clinical benefit in genetically defined patient populations and fulfill the promise of precision medicine for appropriate patients. Cancers Harboring Alterations of Tropomyasin Receptor Kinase (TRK). Loxo Oncology, Inc. Loxo Oncology, Inc.
TOTAL LINKS TO THIS WEBSITE
25
Logitech International - Investor Relations Home
All Featured Press Releases. Stock Quote and Charts. SEC Filings and Additional Disclosures. 2015 Annual General Meeting. All Featured Press Releases. Stock Quote and Charts. SEC Filings and Additional Disclosures. 2015 Annual General Meeting. 2015 Annual General Meeting. September 9, 2015. Deadline for filing Form 10-Q for 2nd quarter ended Sept. 30, 2015. November 4, 2015. Jul 22, 2015. Logitech Confirms FY 2016 Outlook with Q1 Sales of $470 Million. Jul 15, 2015. Jul 09, 2015. Jul 08, 2015.
Online trading services | London Capital Group | LCG
44 (0)20 7456 7000. In line with the EU Cookie Directive we are obliged to inform you that we use cookies to ensure our website provides you with the greatest experience of our service. By using our website, you agree to help us improve our service to you. You can view which cookies we use here. Press and PR Contacts. Welcome to London Capital Group. Annual Financial Report and AGM. Retail customers can place spread bets via Capital Spreads. We offer competitive marketing affiliate. London Capital Group ...
ir.look.in
LOTTE SHOPPING INVESTOR RELATIONS
브라우저에 따라 Alt accessKey 번호 또는 Alt Shift accessKey 번호 또는 Shift Esc accessKey 번호 선택 및 Enter 를 하시면 해당 부분으로 이동합니다. IR 뉴스 / 공시. 4Q 2017 Financial Results. 롯데쇼핑 IR 팀 (02-2118-2020).
Loxo Oncology - Investor Relations - NASDAQ:LOXO
Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. Last Updated: 14 Aug, 2015 4:00 PM (EDT). Minimum 20 minute delay. Loxo Oncology Announces Second Quarter 2015 Financial Results and Provides Program Updates. Aug 5, 2015. Loxo Oncology Appoints Industry Veteran Tim Mayleben to Board of Directors. Jul 30, 2015. Loxo Oncology to Conduct Conference Call and Webcast of Second Quarter Financial Results.
Life Partners Holdings (LPHI) Investor Relations
A Force for Good. Annual Reports and Proxy. From its inception, Life Partners has sought to provide transparency for its clients, and therefore became a publicly traded company. Throughout its corporate history, the company has taken steps to both maximize transparency, as well as provide the utmost protection for its clients investment dollars. This website is designed to further this goal of offering unparalleled transparency to both the owners of our stock, as well as to our clients. Jul 14, 2015.
Office of Institutional Research | Institutional Research - Lenoir-Rhyne University
Institutional Research - Lenoir-Rhyne University. Office of Institutional Research. What is Institutional Research? Peterson (1985) defines institutional research as "a critical intermediary function that links the educational, managerial, and information functions of higher education institutions." Saupe (1981) extends this definition by emphasizing the importance of internal data gathering and analysis to the management of post-secondary educational institutions. Developing and overseeing the implement...
Home
Institutional Research and Effectiveness. Office of Institutional Research and Effectiveness. Main Office: Abrams Hall, Room 109B. The LSUA Office of Institutional Research and Effectiveness (IRE) performs a broad category of work to serve the University. In support of LSUA’s Mission Statement, IRE maintains timely and accurate reporting standards to both external and internal customers. The office is tasked with two main areas of responsibility:. 8100 Hwy 71 South. Alexandria, LA 71302.
Investor Relations | Lightbridge Corporation
Skip to main navigation. Nuclear Utility Fuel Advisory Board. Thorium Based Seed Blanket Technology. Mar 30, 2018. 11710 Plaza America Drive. Reston, VA 20190. Investor Relations: 1.855.379.9900. Main: 1.571.730.1200. Key investment highlights include:. Developed and patented an independently validated metallic nuclear fuel. Completed initial manufacturing and successful testing of the fuel. Addresses growing $25 billion global market for nuclear fuel. Increased power output and enhanced reactor safety.
Corporate Profile
As of August 14, 2015 Minimum 20 minute delay. As of August 14, 2015 -. Minimum 20 minute delay. Thursday, August 6, 2015. Second Quarter 2015 Earnings Conference Call. Friday, May 1, 2015. First Quarter 2015 Earnings Conference Call. Friday, February 27, 2015. Fourth Quarter 2014 Earnings Conference Call. Tuesday, November 4, 2014. Third Quarter 2014 Earnings Conference Call. Thursday, August 7, 2014. Second Quarter 2014 Earnings Conference Call. Thursday, June 5, 2014. LTC Properties, Inc. BMO Capital ...
